Market Report, "Peru Pharmaceuticals & Healthcare Report Q4 2012", Published
BMI View: We continue to view Peru as a moderately attractive pharmaceutical market, on account of elevated risks posed by regulatory and intellectual property (IP) shortcomings and the still-developing healthcare infrastructure. Nevertheless, economic progress and the government-led investment in healthcare facilities and public health programmes pose upside risks to our current forecasts. We also expect Peru's pharmaceutical market to post a local currency compound annual growth rate (CAGR) of 7.6% in the 2011-2016 period, which is only slightly below that...
View full press release